Evaluation of Brain Inflammation Using 18F-DPA-714 PET Imaging in Patients with Intracerebral Hemorrhage

2 1 1

What is this study about?

This study focuses on patients with Intracerebral Hemorrhage, a condition where bleeding occurs inside the brain tissue. The research uses a special imaging substance called 18F-DPA-714, which is given through an intravenous injection to help understand how inflammation affects the brain after bleeding.

The purpose of this research is to examine how the brain’s immune response around the area of bleeding influences a patient’s recovery after six months. The study involves receiving a single injection of 18F-DPA-714 approximately 10 days after the brain bleeding occurs. This substance helps create detailed images of inflammation in the brain using a special type of scan called PET (Positron Emission Tomography).

During the study, participants will undergo brain imaging tests, including MRI scans, to examine how the protective barrier of the brain (called the blood-brain barrier) is affected by the bleeding. Blood samples will also be collected to measure various substances that indicate inflammation in the body. Patients will be monitored for six months to track their recovery progress.

1 Initial brain scan

You will undergo a brain imaging examination to confirm the presence of intracerebral hemorrhage.

This examination must take place within 48 hours after the first symptoms appeared.

2 Pre-inclusion assessment

Medical staff will perform initial evaluations using two scales:

The National Institutes of Health Stroke Scale (NIHSS) to assess stroke severity

The Glasgow Coma Scale to evaluate consciousness level

3 Special imaging procedures

Around day 10 (plus or minus 2 days) after the brain bleeding, you will undergo two types of imaging:

A PET scan using a special substance called 18F-DPA-714, given through an intravenous injection

An MRI scan to examine the area around the bleeding

4 Blood sample collection

Blood samples will be collected around day 10 (plus or minus 2 days) to measure inflammation markers in your blood

5 14-day monitoring period

Your condition will be monitored for changes during the first 14 days after the brain bleeding

Medical staff will regularly check your neurological status using the same scales as in the beginning

6 30-day assessment

Your health status will be evaluated at day 30

7 6-month follow-up

A final assessment will occur 6 months after the brain bleeding

Your functional status will be evaluated using the modified Rankin scale, which measures the degree of disability or dependence in daily activities

Who Can Join the Study?

Must be at least 18 years old
Must have experienced a spontaneous brain bleeding (spontaneous supratentorial intracerebral hemorrhage) in the upper part of the brain
The brain bleeding must have occurred within 48 hours from when symptoms started or when the person was last seen well
The brain bleeding must be confirmed by brain imaging (such as CT scan or MRI)
Must be able to provide informed consent (agreement to participate in the study after understanding its purpose and procedures)
Must have social security coverage or be a beneficiary of a social security scheme

Who Cannot Join the Study?

Age under 18 or over 65 years old
Known pregnancy or positive pregnancy test
History of previous brain hemorrhage (bleeding in the brain)
Current use of blood thinning medications
Presence of brain tumors or other severe brain conditions
Unable to undergo PET scan (special imaging test) due to medical conditions
History of severe allergic reactions to medical contrast agents
Unable to provide informed consent
Participation in other clinical trials in the past 30 days
Severe kidney or liver disease
Life expectancy less than 6 months due to other medical conditions
Recent major surgery within the past 3 months
History of drug or alcohol abuse within the past year
Claustrophobia (fear of confined spaces) that would prevent imaging procedures
Metal implants or devices that would interfere with imaging studies

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Centre Hospitalier Universitaire De Bordeaux	Bordeaux	France
Oncopole Claudius Regaud	Toulouse	France

Other Sites

Site Name	City	Country	Status
Centre Hospitalier Universitaire De Montpellier	Montpellier	France

Trial status

Country	Status	Recruitment Start
France	Not yet recruiting	08.09.2025

Trial locations

18F-DPA-714 is a radioactive tracer used in PET (Positron Emission Tomography) imaging. It helps doctors see inflammation in the brain by binding to specific cells that are active during the inflammatory process. This tracer allows researchers to measure and track inflammation around brain hemorrhages (bleeding) without requiring surgery. It’s not a treatment but rather a diagnostic tool that helps understand how inflammation affects recovery after brain bleeding.

Investigated diseases:

Cerebral haemorrhage

Intracerebral hemorrhage – A condition where blood suddenly leaks or spills into the brain tissue, creating a collection of blood that displaces brain tissue. The bleeding occurs when a blood vessel within the brain bursts, often due to high blood pressure or weakened blood vessel walls. As blood collects in the brain, it forms a mass called a hematoma, which can compress brain tissue. The area around the bleeding site typically develops swelling, known as perihematomal edema. The condition can affect various brain functions depending on the location and size of the bleeding.

Trial ID:

2025-521923-58-00

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Evaluation of Brain Inflammation Using 18F-DPA-714 PET Imaging in Patients with Intracerebral Hemorrhage

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?